Diagonal Bio Ab Stock Price To Earnings To Growth
| DIABIO Stock | 0.03 0 8.84% |
Diagonal Bio AB fundamentals help investors to digest information that contributes to Diagonal Bio's financial success or failures. It also enables traders to predict the movement of Diagonal Stock. The fundamental analysis module provides a way to measure Diagonal Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Diagonal Bio stock.
Diagonal |
Diagonal Bio AB Company Price To Earnings To Growth Analysis
Diagonal Bio's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Diagonal Bio AB has a Price To Earnings To Growth of 0.0 times. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Price To Earnings To Growth (which currently averages 0.0) industry. This indicator is about the same for all Sweden stocks average (which is currently at 0.0).
Did you try this?
Run Odds Of Bankruptcy Now
Odds Of BankruptcyGet analysis of equity chance of financial distress in the next 2 years |
| All Next | Launch Module |
Diagonal Fundamentals
| Return On Equity | -0.52 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (3.67) % | |||
| Current Valuation | 112.69 K | |||
| Shares Outstanding | 34.77 M | |||
| Shares Owned By Insiders | 14.74 % | |||
| Price To Book | 0.50 X | |||
| Price To Sales | 3.26 X | |||
| Revenue | 407 K | |||
| Gross Profit | (85 K) | |||
| EBITDA | (11.66 M) | |||
| Net Income | (11.66 M) | |||
| Book Value Per Share | 2.39 X | |||
| Cash Flow From Operations | (10.94 M) | |||
| Earnings Per Share | (1.83) X | |||
| Market Capitalization | 21.97 M | |||
| Total Asset | 36.01 M | |||
| Net Asset | 36.01 M |
About Diagonal Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Diagonal Bio AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Diagonal Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Diagonal Bio AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Diagonal Stock
Diagonal Bio financial ratios help investors to determine whether Diagonal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diagonal with respect to the benefits of owning Diagonal Bio security.